These findings are supported by analyses of HNSCC patient outcomes that show low STING levels correlate with worse outcomes, suggesting that STING should be investigated as a biomarker in tumor types routinely treated with DNA damaging agents. The gene discussed is STING1; the disease is head and neck squamous cell carcinoma.